Global pandemics interconnected - obesity, impaired metabolic health and COVID-19

Obesity and impaired metabolic health are established risk factors for the non-communicable diseases (NCDs) type 2 diabetes mellitus, cardiovascular disease, neurodegenerative diseases, cancer and nonalcoholic fatty liver disease, otherwise known as metabolic associated fatty liver disease (MAFLD)....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Nature reviews. Endocrinology Ročník 17; číslo 3; s. 135 - 149
Hlavní autoři: Stefan, Norbert, Birkenfeld, Andreas L, Schulze, Matthias B
Médium: Journal Article
Jazyk:angličtina
Vydáno: England Nature Publishing Group 01.03.2021
Témata:
Cardiovascular diseases
Coronaviridae
Coronaviruses
COVID-19
COVID-19 - epidemiology
COVID-19 - virology
COVID-19 vaccines
Diabetes mellitus (non-insulin dependent)
Fatty liver
Humans
Hyperglycemia
Inflammation
Liver cancer
Liver diseases
Metabolism
Mortality
Neurodegenerative diseases
Obesity
Obesity - epidemiology
Pandemics
Risk Factors
SARS-CoV-2 - pathogenicity
Severe acute respiratory syndrome coronavirus 2
ISSN:1759-5029, 1759-5037, 1759-5037
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Obesity and impaired metabolic health are established risk factors for the non-communicable diseases (NCDs) type 2 diabetes mellitus, cardiovascular disease, neurodegenerative diseases, cancer and nonalcoholic fatty liver disease, otherwise known as metabolic associated fatty liver disease (MAFLD). With the worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), obesity and impaired metabolic health also emerged as important determinants of severe coronavirus disease 2019 (COVID-19). Furthermore, novel findings indicate that specifically visceral obesity and characteristics of impaired metabolic health such as hyperglycaemia, hypertension and subclinical inflammation are associated with a high risk of severe COVID-19. In this Review, we highlight how obesity and impaired metabolic health increase complications and mortality in COVID-19. We also summarize the consequences of SARS-CoV-2 infection for organ function and risk of NCDs. In addition, we discuss data indicating that the COVID-19 pandemic could have serious consequences for the obesity epidemic. As obesity and impaired metabolic health are both accelerators and consequences of severe COVID-19, and might adversely influence the efficacy of COVID-19 vaccines, we propose strategies for the prevention and treatment of obesity and impaired metabolic health on a clinical and population level, particularly while the COVID-19 pandemic is present.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1759-5029
1759-5037
1759-5037
DOI:10.1038/s41574-020-00462-1